infants at highest risk of RSV

Access & Financial Assistance

SYNAGIS CONNECT® offers support to help appropriate 
patients get access to SYNAGIS.

Infants at highest risk RSV

SYNAGIS Access

Help your highest-risk RSV patients get SYNAGIS

SYNAGIS CONNECT® is a support program that provides options for patient healthcare coverage and financial assistance information that may be available to help appropriate patients get access to SYNAGIS.*

SYNAGIS Connect logo

Enroll now or call

1-833-SYNAGIS (1-833-796-2447) Monday–Friday 8 AM–8 PM ET

*SYNAGIS CONNECT® is not a CoverMyMeds LLC program or solution. SYNAGIS CONNECT® is owned and operated solely by Sobi, Inc. 

Eligibility requirements apply: Patient must be a resident of the US or Puerto Rico. Patient must be commercially insured. There are no income requirements to participate in the program. Patient must not be insured by any government, state, or federally funded prescription program, including Medicare, Medicaid, Medigap, VA, DOD, or TRICARE.

SYNAGIS Copay Assistance Program

The SYNAGIS Copay Assistance Program helps eligible patients with commercial insurance manage out-of-pocket costs. Patients may save up to a maximum of $6,000 per calendar year. See terms and conditions.

Pay As Little As 0 Dollars Copay Icon

DISCLAIMER: The SYNAGIS Copay Assistance Program covers only the cost of the medication, not the cost of administration.

 

Enroll now or call

1-833-SYNAGIS (1-833-796-2447) Monday–Friday 8 AM–8 PM ET

 

How to Order SYNAGIS

How To Order Icon

SYNAGIS is only available for order through approved Specialty Distributors

Cencora

Phone: 800-746-6273

Fax: 800-547-9413

Email: asd.customerservice@asdhealthcare.com

Web: asdhealthcare.com

McKesson Plasma and Biologics

Phone: 877-625-2566

Fax: 888-752-7626

Email: mpborders@mckesson.com

Web: connect.mckesson.com

Cardinal Health Specialty Distribution

Phone: 855-855-0708

Fax: 877-274-9897

Email: gmb-spd-csorderentry@cardinalhealth.com

Acute, retail, and specialty pharmacies: orderexpress.cardinalhealth.com

Web: specialtyonline.cardinalhealth.com

McKesson Specialty Care Distribution

Phone: 855-477-9800

Email: msh.customercare-mspl@mckesson.com

Web: mscs.mckesson.com/CustomerCenter

CuraScript SD

Phone: 877-599-7748

Fax: 800-862-6208

Email: Customer.Service@curascript.com

Web: curascriptsd.com

Cardinal Health Puerto Rico 
(Puerto Rico and US Territories)

Phone: 800-981-4699 or 787-625-4200

Fax: 787-625-4398

Email: cuserv@cardinalhealth.com

Online via Order Express: orderexpress.cardinalhealth.com

Online via Specialty Health: specialtyonline.cardinalhealth.com

SYNAGIS is only available through a Limited Distribution Specialty Pharmacy Network

Order SYNAGIS® (palivizumab) by calling or faxing prescriptions to these specialty pharmacies.

AcariaHealth

Phone: 1-855-422-2742

Fax: 1-877-252-2444

Accredo

Phone: 1-877-482-5927 (opt. 3)

Fax: 1-877-369-3447

 

Advanced Pharmacy Solutions

Phone: 1-800-464-7736 (opt. 3)

Fax: 1-949-582-6111

AllianceRx Walgreens Prime

Phone: 1-888-282-5166

Fax: 1-888-570-4700

CenterWell Specialty Pharmacy

Phone: 1-800-486-2668

Fax: 1-877-405-7940

CVS Specialty Pharmacy 
(Including US Bioservices)

Phone: 1-800-753-2777 (ext. 1307886)

Fax: 1-800-323-2445

Duncan Specialty Pharmacy

Phone: 1-270-247-3725

Fax: 1-270-247-6033

Lumicera Health Services

Phone: 1-855-847-3553 (opt. 8)

Fax: 1-855-847-3558

Optum Specialty Pharmacy

Phone: 1-888-293-9309 (opt. 1)

Fax: 1-866-391-1890

Vital Care Rx

Phone: 1-877-229-1724

Fax: 1-877-229-1725

In Puerto Rico

Special Care Pharmacy Services

Phone: 1-787-781-4585

Fax: 1-787-783-2951

NICU=neonatal intensive care unit; RSV=respiratory syncytial virus. 

All imagery is for illustrative purposes only.

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Anaphylaxis and anaphylactic shock (including fatal cases) and other severe acute hypersensitivity reactions have been reported. Permanently discontinue SYNAGIS and administer appropriate medication if such reactions occur.

Coagulation Disorders: SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.

RSV Diagnostic Test Interference: Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Serious Adverse Reactions: The most common serious adverse reactions occurring with SYNAGIS are anaphylaxis and other acute hypersensitivity reactions.

Most Common Adverse Reactions: The most common adverse reactions are fever and rash.

Postmarketing Experience: Severe thrombocytopenia and injection site reactions have been identified during post approval use of SYNAGIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

CONTRAINDICATIONS

Previous significant hypersensitivity reaction to SYNAGIS.

INDICATION

SYNAGIS, 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

  • with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
  • with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
  • with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

 

These are not all the possible risks associated with SYNAGIS. Please see full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or the FDA at 1-800-FDA-1088.

For WAC pricing, visit synagishcp.com/wac-pricing.